Remove 2023 Remove Pharmaceutical Companies Remove Pharmaceutical Manufacturing
article thumbnail

Key developments in pharmaceutical manufacturing – September 2023

European Pharmaceutical Review

September 2023 saw a wave of new pharmaceutical manufacturing facility expansions and launches across Europe. Research by the Confederation of British Industry (CBI) , released in September this year, highlighted progress for UK manufacturing in its latest Industrial Trends Survey. Meath opened last month.

article thumbnail

PDA revises report on glass container manufacturing

European Pharmaceutical Review

Revised for 2023, the Parenteral Drug Association (PDA) has published an update to its Technical Report No. 43: Identification and Classification of Nonconformities in Moulded and Tubular Glass Containers for Pharmaceutical Manufacturing.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Technology innovation aiding process spectroscopy market growth

European Pharmaceutical Review

Innovations in the process spectroscopy market molecular spectroscopy accounted for the greatest share of the process spectroscopy market between 2023 to 2033″ The analysis found that molecular spectroscopy accounted for the greatest share of the process spectroscopy market between the 2023 to 2033 forecast period.

article thumbnail

Who’s saying what? Environmental sustainability mentions in company filings of pharmaceutical industry increased by 114% in Q1 2023

Pharmaceutical Technology

The global pharmaceutical industry experienced a 114% rise in company filings mentions of environmental sustainability in Q1 2023 compared with the previous quarter, with the highest share accounted for by Novozymes with 27% year-on-year increase, according to GlobalData’s analysis of over 757 pharmaceutical company filings.

article thumbnail

Innovative radioligand manufacturing facility inaugurated

European Pharmaceutical Review

The first industrial-scale pharmaceutical manufacturing facility for production of lead-212-based radioligand therapies has been inaugurated. Radioligand therapy developments in 2023 and 2024 Other companies making progress producing radioligand therapies include Novartis. billion.

article thumbnail

QMS market to value nearly $4b by 2030

European Pharmaceutical Review

Adoption of QMS within pharma and biopharma is increasing due to strict regulations, frequent changes in the manufacturing process and higher demand to increase production capacity. Some pharmaceutical companies are increasing their R&D spending to increase product numbers.

article thumbnail

Who’s innovating where? Environmental sustainability related patent filings activity decreased by 23% in the pharmaceutical industry in Q1 2023

Pharmaceutical Technology

The global pharmaceutical industry experienced a 23% decline in the number of environmental sustainability-related patent applications in Q1 2023 compared with the previous quarter. The total number of environmental sustainability-related grants dropped by 24% in Q1 2023, according to GlobalData’s Patent Analytics. in Q1 2023.